New drug shows promise against rare salivary gland cancer

NCT ID NCT02780310

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests the drug lenvatinib in 33 people with advanced adenoid cystic carcinoma that has returned or spread. Lenvatinib is a daily pill that blocks cancer cell growth and cuts off blood supply to tumors. The main goal is to see if the drug can shrink tumors by at least 25%.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Mercy Medical Center

    Rockville Centre, New York, United States